Halothane effect on beta-adrenergic receptors in canine myocardium

Area of Science:

• Cardiology
• Anesthesiology
• Pharmacology

Background:

• Halothane is known to depress cardiac inotropy, potentially by reducing cyclic adenosine monophosphate (cAMP) formation.
• Adenylate cyclase activity, responsible for cAMP generation, may be inhibited by halothane.
• Catecholamines influence cardiac contractility and adenylate cyclase via myocardial beta-adrenergic receptors.

Purpose of the Study:

• To investigate whether halothane affects myocardial beta-adrenergic receptor binding.
• To determine if beta-adrenergic receptor interactions are a site of halothane's cardiac effects.

Main Methods:

• In vitro study using canine myocardial membrane preparations.
• Measurement of beta-adrenergic receptor binding equilibrium in the presence and absence of halothane (3-5 vol%).
• Use of radioligand 3H-dihydroalprenolol (3H-DHA), a beta-adrenergic antagonist, to assess receptor affinity and number.
• Assessment of halothane's effect on the binding of l-isoproterenol, a beta-adrenergic agonist, by displacing 3H-DHA.

Main Results:

• Halothane did not alter the affinity of canine myocardial beta-adrenergic receptors for 3H-DHA.
• Halothane did not affect the affinity of beta-adrenergic receptors for the agonist l-isoproterenol.
• The number of available beta-adrenergic receptors at binding equilibrium remained unchanged in the presence of halothane.

Conclusions:

• Halothane does not interact with myocardial beta-adrenergic receptors.
• The observed cardiac depression by halothane is unlikely to be mediated through alterations in beta-adrenergic receptor binding characteristics.